Setting a high threshold for noninferiority: Mesalamine and budesonide in Crohn's disease
Article first published online: 7 JUL 2011
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 4, pages 795–796, April 2012
How to Cite
Levesque, B. G. and Sandborn, W. J. (2012), Setting a high threshold for noninferiority: Mesalamine and budesonide in Crohn's disease. Inflamm Bowel Dis, 18: 795–796. doi: 10.1002/ibd.21813
- Issue published online: 19 MAR 2012
- Article first published online: 7 JUL 2011
- Manuscript Accepted: 2 JUN 2011
- Manuscript Received: 23 MAY 2011
- 2Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010; 8: CD008870., .
- 5Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002; 97: 1748–1754., , , et al.Direct Link:
- 8Fundamentals of Clinical Trials. 4th ed. New York, NY: Springer Science & Business Media; 2010., , .